News
Mission drives innovation, and innovation improves quality of life
News
-
TargetRx Signs Collaboration Agreement With Simcere Zaiming2024-09-02 Views:83
September 2, 2024 - Shenzhen TargetRx, Inc (TargetRx) announced that it has recently entered into a collaboration ...
-
ASH 2023| TargetRx announced the results of the phase I clinical trial and preclinical study of TGRX-678 2023-12-15 Views:394
Shenzhen TargetRx,Inc (hereinafter referred to as "TargetRx "), a biotech company focus on developing precision targ ... -
ASH 2023 | TargetRx to highlight advances of TGRX-678 in CML2023-11-03 Views:213
The 65th Annual Meeting of the American Society of Hematology (ASH) will be held in San Diego, USA, from Decemb ... -
TargetRx to present PhaseⅠclinical data of TGRX-326 at the 2023 ASCO Annual Meeting2023-05-05 Views:312
TargetRx will present clinical data from PhaseⅠstudy of TGRX-326 in Advanced ALK-positive non-small cell lung canc ... -
TargetRx was awarded the "2021 China's Top 100 Pharmaceutical R&D Strength Series"2021-09-26 Views:318
"2021 China s Top 100 Pharmaceutical R&D Strength Series " is evaluated by the YAOZHI com, the committee of China Pharmaceutical R&D-Summit Organizing Committee and China Pharmaceutical, referring to the R&D-related data... -
TargetRx announces dosing of first subject in phase I clinical trial of TGRX-326, a next-generation ALK inhibitor for non-small cell lung cancer2021-07-01 Views:543
Recently, Shenzhen TargetRx Inc (hereinafter referred to as TargetRx) announced that the first subject has been dosed with the ALK ROS1 inhibitor TGRX-326, a Class 1 innovative new drug for treatment of non-small cell lung cancer, in (First-in-Human) ...
Tel: +86-0755-86934300
3rd Floor, Building A1, Kexing Science Park, No. 15 Keyuan Rd., Nanshan District, Shenzhen, China
E-mail: 